AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02847130 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Undergo one-on-one interviews
Study NCT02847130 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study NCT02847130 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01680900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
Study NCT01680900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: placebo capsules matched to drug capsules.
Study NCT04695964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICG-NIRF Imaging plus ingress and egress analysis
Description: intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3) Additional ingress and egress analysis (inflow and outflow analysis) of specificities regions of interest at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
Study NCT04545346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glutamate diet
Description: Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
Study NCT00898560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate and Microginon®
Description: eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period
Study NCT00898560 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Microginon®
Description: Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
Study NCT01677715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Mei Yi Tian active lactobacillus drink
Description: 100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention
Study NCT01677715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: recombined milk drink contains no lactobacillus
Description: 100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
Study NCT03887754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
Study NCT00999037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate
Description: Daily renvela (800 mg tid with meals) x 12 weeks
Study NCT00999037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 inert tablet tid x 12 weeks
Study NCT03887754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.
Study NCT03887754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non specific Multivitamin
Description: control group received non specific multivitamins as placebo for 8 months.
Study NCT03413150 — intervention group
Intervention type: DRUG
Intervention: Amiodarone
Description: Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
Study NCT01490619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Thinking In Teens
Description: 9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
Study NCT01490619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Diabetes Education.
Description: 9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
Study NCT00865020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
Study NCT00865020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
Study NCT00865020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
Study NCT00865020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Telmisartan
Description: Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
Study NCT00782366 — intervention group
Intervention type: GENETIC
Intervention: SNP analysis
Description: The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
Study NCT02154412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Training
Description: Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) \& an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
Study NCT00996099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment
Description: Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
Study NCT00996099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intensive insulin therapy using standard protocol
Description: Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
Study NCT01582308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Study NCT00105196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole+ ADT
Description: Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
Study NCT01582308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Study NCT01582308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg
Description: Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Study NCT01582308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg BID
Description: Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
Study NCT01582308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Study NCT03373604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240
Description: 18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
Study NCT03373604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-MK-6240
Description: 18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
Study NCT03373604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
Study NCT03373604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture (optional)
Description: Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
Study NCT00726687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: indibulin, dose escalation, 400-600 mg taken twice every day
Study NCT00726687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
Study NCT01382693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TimeSlips
Description: TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
Study NCT01382693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care activity program
Description: Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
Study NCT04686630 — intervention group
Intervention type: OTHER
Intervention: Video based observational gait analysis and SCALE Test
Description: Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
Study NCT02490293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporin
Description: During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days.
Study NCT02490293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days.
Study NCT02705989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986195
Description: Specified dose on specified day
Study NCT02705989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: Specified dose on specified day
Study NCT02705989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified day
Study NCT05628220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: rehabilitation through using session of virtual reality desensitization
Study NCT01964352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination
Study NCT01964352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01964352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination
Study NCT01964352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Study NCT00105196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ ADT
Description: Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
Study NCT03340727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
Study NCT03340727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
Study NCT01921920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
Study NCT01850056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting balloon catheter (trade name: Orchid)
Study NCT01850056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)
Study NCT00166205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swedish Adjustable Gastric Band
Description: Long term implantable device.
Study NCT03314545 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laminate veneer with coronal post
Description: laminate veneer with coronal post
Study NCT03314545 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: post,core and crown
Description: post,core and crown
Study NCT03772626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Humidified High-flow Nasal Cannula
Description: Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
Study NCT01823679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally
Study NCT03842826 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Palpation, resistance and stretch tests
Description: Palpation, resistance and stretch tests performed by 2 blinded examiners.
Study NCT02164981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitroprusside
Description: intravenous
Study NCT02164981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sodium nitroprusside
Description: intravenous
Study NCT02164981 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00465959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trospium chloride inhalation powder (TrIP)
Study NCT00465959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00809770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
Study NCT00809770 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non Contingent Control Condition
Description: Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
Study NCT00144898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Node Resection
Description: Sentinel Node Resection
Study NCT00144898 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Axillary Dissection
Description: Conventional Axillary Dissection
Study NCT01039337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip School
Description: The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
Study NCT01039337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip School and Manual Treatment
Description: Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
Study NCT01039337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal control intervention
Description: As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
Study NCT01526512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metroCX
Description: cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
Study NCT04711772 — intervention group
Intervention type: OTHER
Intervention: whole-genome sequencing
Description: Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.
Study NCT03536455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study NCT03536455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study NCT01490658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Study NCT01490658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Study NCT01490658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Study NCT01490658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Study NCT01490658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide and metformin combination tablet
Description: Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Study NCT01490658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide and metformin combination tablet
Description: Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Study NCT01972230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study NCT01972230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan + Remifentanil TCI
Study NCT02969057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast with rice bran oil gel
Description: 25 grams of rice bran oil gel